76003-29-7

Basic information

• Product Name: 1-Boc-3-oxopiperazine
• Synonyms: tert-Butyl 3-oxopiperazine-1-carboxylate, 1-(tert-Butoxycarbonyl)-3-oxopiperazine;1-Boc-oxopiperzine;1-Boc-3-oxopiperazine 3-Oxopiperazine-1-carboxylic Acid tert-Butyl Ester;1-(tert-Butoxycarbonyl)piperazin-3-one;1-Boc-3-oxopiperazine 98%;1-Boc-3-oxopiperazine SynonyMs 4-N-Boc-2-oxo-piperazine;1-Boc-3-oxopiperazine,98%;1-Piperazinecarboxylic acid, 3-oxo-, 1,1-dimethylethyl ester
• CAS NO: 76003-29-7
• Molecular Formula: C₉H₁₆N₂O₃
• Molecular Weight: 200.23
• Product Categories: Building Blocks;C9;Chemical Synthesis;Heterocyclic Building Blocks;pharmacetical;Building Blocks;Heterocyclic Building Blocks;Piperazines
• Mol File: 76003-29-7.mol

Chemical Properties

• Melting Point: 156-160 °C(lit.)
• Boiling Point: 359.1 °C at 760 mmHg
• Flash Point: 171 °C
• Appearance: White to off-white/Crystalline Powder
• Density: 1.129 g/cm³
• Vapor Pressure: 2.44E-05mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 15.01±0.20(Predicted)
• CAS DataBase Reference: 1-Boc-3-oxopiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-3-oxopiperazine(76003-29-7)
• EPA Substance Registry System: 1-Boc-3-oxopiperazine(76003-29-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 76003-29-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-3-oxopiperazine is used as a synthetic intermediate for the development of renin inhibitors. These renin inhibitors are designed to treat hypertension and heart failure by blocking the activity of the enzyme renin, which plays a crucial role in the regulation of blood pressure.
Additionally, 1-Boc-3-oxopiperazine is used as a synthetic intermediate for the development of isoindoline inhibitors of dipeptidyl peptidases (DPPs). DPPs are a group of enzymes involved in the degradation of peptides, and their inhibition has been linked to the treatment of various diseases, including diabetes, neurodegenerative disorders, and cancer. The synthesis of isoindoline inhibitors using 1-Boc-3-oxopiperazine allows for the creation of potent and selective DPP inhibitors, which can be further optimized for therapeutic applications.

InChI:InChI=1/C9H16N2O3/c1-9(2,3)14-8(13)11-5-4-10-7(12)6-11/h4-6H2,1-3H3,(H,10,12)

Upstream product

• 5625-67-2 2-Ketopiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 107-06-2 1,2-dichloro-ethane 
• 105-39-5 chloroacetic acid ethyl ester 
• 75-65-0 tert-butyl alcohol 
• 179051-25-3 1-(2-naphthylmethyl)-2-oxopiperazine trifluoroacetate salt 

Downstream Products

• 76003-34-4 t-Butyl 3-oxo-2-benzylidenyl-1-piperazinecarboxylate 
• 76003-35-5 methyl 4-(t-Butoxycarbonyl)-2-oxo-3-(4-benzyloxybenzyl)-1-piperazineacetate 
• 76003-33-3 t-Butyl 3-oxo-2-phenylthio-1-piperazinecarboxylate 
• 76003-32-2 t-Boc-3-(p-benzyloxybenzyl)-piperazinon 
• 78551-60-7 1-benzyl-4-(tert-butyloxycarbonyl)piperazin-2-one 
• 76003-30-0 tert-butyl 2-methyl-3-oxopiperazine-1-carboxylate 
• 76003-31-1 t-Butyl 3-Oxo-2-benzyl-1-piperazinecarboxylate 
• 267659-63-2 1-[2-Bromo-5-((methanesulfonyl)oxy)benzyl]-4-tert-butoxycarbonyl-2-piperazinone 
• 367268-84-6 4-[2-chloro-5-(methanesulfonyloxy)-benzyl]-3-oxopiperazine-1-carboxylic acid tert-butyl ester 
• 367268-98-2 4-[2-fluoro-5-(methanesulfonyloxy)-benzyl]-3-oxo-piperazine-1-carboxylic acid tert-butyl ester 
• 930122-19-3 4-(2-methoxy-2-oxoethyl)-3-oxopiperazine-1-carboxylic acid tert-butyl ester 
• 444002-56-6 4-(4-amino-phenyl)-3-oxopiperazine-1-carboxylic acid tert-butyl ester 
• 309915-36-4 tert-butyl 4-(4-fluorobenzyl)-3-oxopiperazine-1-carboxylate 
• 914104-09-9 tert-butyl 4-[4-(2-{[(benzyloxy)carbonyl]amino}ethyl)benzyl]-3-oxopiperazine-1-carboxylate 

Relevant articles and documents

Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation

Alzheime?s disease (AD) is the most prominent neurodegenerative disorder with high medical need. Protein-protein-interactions (PPI) interactions have a critical role in AD where β-amyloid structures (Aβ) build toxic oligomers. Design of disease modifying multi target directed ligand (MTDL) has been performed, which disable PPI on the one hand and on the other hand, act as procognitive antagonists at the histamine H3 receptor (H3R). The synthetized compounds are structurally based on peptidomimetic amino acid-like structures mainly as keto, diketo-, or acyl variations of a piperazine moiety connected to an H3R pharmacophore. Most of them showed low nanomolar affinities at H3R and some with promising affinity to Aβ-monomers. The structure–activity relationships (SAR) described offer new possibilities for MTDL with an optimized profile combining symptomatic and potential causal therapeutic approaches in AD.

Nitroimidazole compound as well as preparation method and application thereof

The invention discloses a novel nitroimidazole compound as well as a preparation method and application thereof. The nitroimidazole compound has a general formula (I) shown in the specification.

The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a

We present the first application of hydrophobic tagging to a non-covalent inhibitor of protein-protein interactions. Nutlin-3a-HT, created by fusing the hydrophobic tag HyT13 to the MDM2-p53 interaction inhibitor Nutlin-3a, prevented cellular accumulation of MDM2 upon p53 reactivation, and had a stronger effect on cell viability and the induction of apoptosis than Nutlin-3a.

Tetrahydroisoquinoline amide compounds containing quaternary ammonium ion and pharmaceutical use thereof

The invention relates to tetrahydroisoquinoline amide compounds containing quaternary ammonium ion, a preparation method of the compounds, and a use of the compounds in the treatment or prevention ofthromboembolic diseases.

PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Dimer ester micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase

The invention provides dimer ester micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase. The structure of the PROTACs is shown in the specification, wherein in a compound (I), L1 is C1-C30 linear or branched alkyl with or without a substituent group, and any carbon atom in L1 is optionally replaced by heteroatom; R1, R2, R3 and R4 are C1-C30 linear or branched alkyl with orwithout a substituent group, C1-C30 aryl with or a without substituent group, C1-C30 linear or branched alkylaryl with or without a substituent group or C1-C30 linear or branched aryl alkyl with or without a substituent group respectively and independently; X1, X2, X3 and X4 are halogen respectively and independently.

Dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase

The invention provides dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase. The structure of the PROTACs is shown in the specification, wherein in a compound (I), L1 is C1-C30 linear or branched alkyl with or without a substituent group, and any carbon atom in L1 is optionally replaced by heteroatom; R1, R2, R3 and R4 are C1-C30 linear or branched alkyl with orwithout a substituent group, C1-C30 aryl with or without a substituent group, C1-C30 linear or branched alkylaryl with or without a substituent group or C1-C30 linear or branched aryl alkyl with or without a substituent group respectively and independently; X1, X2, X3 and X4 are halogen respectively and independently.

Containing piperazinone quinazoline ketone PARP - 1/2 inhibitor and its preparation method, pharmaceutical composition and use thereof (by machine translation)

The invention discloses a new class of containing piperazinone quinazoline - 2, 4 (1 H, 3 H) - dione PARP - 1/2 inhibitor, and its preparation and pharmaceutical composition and use. Specifically, the invention relates to the general formula I shown containing of the piperazinone quinazoline - 2, 4 (1 H, 3 H) - dione derivatives and their pharmaceutically acceptable salt, and its preparation method, comprising one or more of the compounds of the composition, and the compounds in the preparation, the prevention and/or treatment with PARP - 1/2 of a disease associated with the use of the medicament. (by machine translation)

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.